Is screening for gonorrhea and chlamydia cost-effective in reducing the cumulative incidence of these infections in men who have sex with men taking HIV pre-exposure prophylaxis (PrEP): a randomized, multicenter controlled trial

Project Details


This study is a multi-centre, controlled, randomized trial of 3x3 Ng/Ct screening (comparator) vs. no screening (intervention). It will be performed in the PrEP cohorts situated at the ITM, HSP, CHU, UZG and EH. All men in follow up at these five centres who report having had sex with another man in the previous year and are enrolled for PrEP follow up will be eligible to participate in the study. After signing informed consent participants will be randomized via a computer-generated schema to either 3x3 screening or no Ng/Ct screening (see section 8.3). In both arms, participants will be followed up in an identical fashion including 3x3 screening. The only difference between the arms will be that in the screening arm, Ng/Ct results will be sent by the STI Laboratory to the study physicians and these participants will be treated and partner contact tracing will be done. The STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study. In both arms, all individuals with symptoms compatible with Ng or Ct will be tested and treated for these infections according to current best practice guidelines. At the end of the 12-month study period, participants whose most recent tests were positive for Ng or Ct will receive treatment for these.
AcronymGonoScreen: Efficacy of screening STIs in MSM
Effective start/end date1/07/2030/06/24


  • Belgian Health Care Knowledge Centre: €1,618,778.42